Leaders at GlaxoSmithKline (GSK) and Innoviva Inc. recently announced the results of the new Salford Lung Study (SLS) in Chronic Obstructive Pulmonary Disease (COPD), which shows that using Relvar Ellipta instead of traditional treatments gives COPD patients greater relief.
Biogen recently stated that its investigational treatment for early Alzheimer’s disease (AD), aducanumab, has been accepted into the Priority Medicines (PRIME) program of the European Medicines Agency (EMA).
Astellas Pharma Inc. and Medivation Inc. recently announced that it will initiate its new phase-three clinical trial to evaluate the safety and efficacy of enzalutamide for treating patients who have triple-negative breast cancer (TNBC).
Axumin, a radioactive diagnostic agent for injections, recently received approval from the U.S. Food and Drug Administration (FDA), as the new technology may be useful in detecting recurrent prostate cancer.
Boehringer Ingelheim, a pharmaceutical company focused on research, recently announced that it seeks to improve the access that HIV and AIDS patients have to antiretroviral medication to treat their illnesses.
Leaders at the annual meeting of the American Academy of Neurology recently announced some important progress that has been made with regard to understanding and treating amyotrophic lateral sclerosis (ALS).
Organizers of the One Brave Idea research funding opportunity recently announced the 10 finalists who have been chosen for the last round of the competition, which gives the winner $75 million for research.